Arachnoid Cysts Treatment Market – By Type (Intracranial Arachnoid Cysts), Diagnosis (CT Scan, MRI Scan), Treatment Type (Endoscopic Cysts Fenestration), End-use (Hospitals, Ambulatory Surgical Centers) – Global Forecast (2024 ­ 2032)

Arachnoid Cysts Treatment Market Size

Arachnoid Cysts Treatment Market size was valued at USD 1.3 Billion in 2023 growing at a CAGR of 5.7% between 2024 and 2032, driven by factors such as the rising incidence and prevalence of arachnoid cysts attributed to factors such as improved diagnostic techniques and an aging population, contribute to the expansion of the treatment market.
 

Moreover, advancement in diagnostic technologies, in neuroimaging techniques, such as MRI and CT scans, allow for more accurate and early detection of arachnoid cysts. This drives the demand for treatment options as patients are diagnosed at earlier stages. For instance, in June 2022, Siemens Healthineers introduces Symbia Pro.specta, a single photon emission computed tomography/computed tomography (SPECT/CT) system with CE mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging technologies. Symbia Pro.specta is an all-purpose system that can be customized to accommodate a wide range of clinical exams, patient types, and department settings.
 

Arachnoid cysts are the most common type of brain cyst. They are often congenital, or present at birth. Head injury or trauma can also result in a secondary arachnoid cyst. They affect people of all ages, but they arise in babies and children. Males are four times more likely to develop an arachnoid cyst than females. Treatment depends on where the cyst is and if it is growing or causing symptoms.
 

Arachnoid Cysts Treatment Market Trends

• The rise in advancements in neuroimaging technology have significantly propelled the growth of the market by revolutionizing the diagnosis, treatment planning, and post-treatment monitoring of patients with this neurological condition. Moreover, real-time intraoperative imaging technologies such as intraoperative MRI or CT provide neurosurgeons with invaluable visual guidance during surgical procedures, ensuring optimal cyst fenestration while minimizing the risk of complications.
   
• For instance, in January 2024, Hyperfine, Inc. announced the launch of the AI-powered eighth generation of Swoop system software. The software’s diffusion-weighted imaging (DWI) AI denoising feature received U.S. Food and Drug Administration (FDA) clearance in October 2023. The latest software improves Swoop system image quality and introduces valuable ease-of-use features, including a real-time aid for more precise patient loading and positioning and a streamlined image upload process.
   

Arachnoid Cysts Treatment Market Analysis

Based on the type, the global market is classified into intracranial arachnoid cysts and spinal arachnoid cysts. The intracranial arachnoid cysts segment dominated the market with revenue of USD 739.8 million in 2023.
 

• The growing awareness among healthcare professionals and the patient about intracranial arachnoid cysts leads to more frequent detection and diagnosis of the disease condition, driving demand for treatment options.
   
• Moreover, the rise in technological advancements in neuroimaging techniques such as MRI and CT scans enable more accurate and early detection of intracranial arachnoid cysts, contributing to market growth by increasing the number of identified cases, and hence propel the growth of the market.
   

Based on the diagnosis, the global arachnoid cysts treatment market is classified into CT scan, MRI scan, prenatal ultrasound, and other diagnosis. The CT scan segment dominated the market with market share of 54.3% in 2023.
 

• CT scans play a crucial role in the diagnosis, treatment planning, and monitoring of arachnoid cysts. The various advantages offered by CT scan such as accuracy in diagnosis, accessibility and availability, speed and efficiency and improved image quality as compared to other diagnosis devices drive the growth of CT scans in the market.
   
• Moreover, compared to MRI, CT scans are generally more cost-effective and accessible, making them a preferred imaging modality in resource-constrained healthcare settings. The cost-effectiveness of CT scans contributes to the widespread use in the evaluation and management of arachnoid cysts.
   

Based on treatment type, the arachnoid cysts treatment market is classified into endoscopic cysts fenestration, fenestration, and permanent drainage system surgery. The endoscopic cysts fenestration segment is expected to exhibit 6.2% CAGR between 2024 - 2032.
 

• Endoscopic cyst fenestration is increasingly recognized as an effective treatment option for arachnoid cysts, particularly in cases where surgical intervention is necessary. The rise in the demand for minimally invasive surgical procedures and shorter hospital stays are the major factors that contribute to the growth of the endoscopic cysts fenestration market.
   
• Moreover, the ongoing advancements in endoscopic instrumentation, surgical techniques, and imaging modalities have further improved the safety and efficacy of cyst fenestration procedures. Thus, this will increase the demand for endoscopic cysts fenestration treatment type, that boost the growth of the market, during the forecast period.
   

Based on end-use, the arachnoid cysts treatment market is classified into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment is expected to exhibit 6.1% CAGR between 2024 - 2032.
 

• Hospitals play a central role in providing comprehensive care to patients with arachnoid cysts, contributing to market growth. The rising incidence and prevalence of arachnoid cysts worldwide drive demand for healthcare services, including diagnosis, treatment, and management.
   
• Moreover, hospitals often have access to advanced diagnostic and imaging technologies, such as MRI, CT scans, and neuroimaging modalities, which are essential for accurate diagnosis and treatment planning of arachnoid cysts. The availability of these facilities attracts patients seeking specialized care for the disease condition.
   

In 2023, North America secured a substantial market share of 44.1% in the global arachnoid cysts treatment market and is expected to dominate throughout the forecast period.
 

• North America has one of the highest healthcare expenditures globally, driven by factors such as increasing healthcare demand, technological advancements, and aging demographics.
   
• Higher healthcare spending translates into greater investment in diagnostic, therapeutic, and surgical interventions for conditions like arachnoid cysts, stimulating market growth.
   
• In addition, stringent regulatory oversight in North America ensures the safety, efficacy, and quality of medical devices, pharmaceuticals, and healthcare services. Compliance with regulatory requirements instills confidence among patients, healthcare providers, and investors, fostering innovation and growth in the market.
   

The arachnoid cysts treatment market in U.S. is expected to exhibit 5.9% CAGR between 2024 - 2032.
 

• The presence of advanced healthcare infrastructure in U.S. with advanced diagnostic and treatment technologies for arachnoid cysts stimulating the market growth.
   
• Moreover, the increase in the diagnostic rate of arachnoid cysts owing to rise in awareness among healthcare professionals and patients drive patient engagement and demand for treatment services, fueling market growth.
   

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.
 

• The presence of prominent industry players, along with increase in research and development activities, leading to the development of advanced diagnostic tools, surgical techniques, and medical devices for the treatment of arachnoid cysts. Thus, the rise in technological innovations improves treatment outcomes and stimulates market growth.
   
• Moreover, health insurance coverage for the treatment of a wider range of options for arachnoid cysts, driving market growth as adequate insurance coverage reduces financial barriers to treatment.
   

Arachnoid Cysts Treatment Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical and medical device companies that involved in manufacturing of diagnostic devices vying for market share. Key players are engaging in strategic initiatives such as acquisitions, collaboration, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for medical devices used in arachnoid cysts treatment.
 

Arachnoid Cysts Treatment Market Companies

Prominent players operating in the market are as mentioned below:

• Aesculap Inc.
• B. Braun Melsungen AG
• FUJIFILM Sonosite Inc.
• GE Healthcare
• Integra Life Sciences
• Karl Storz
• Koninklijke Philips N.V
• Medtronic PLC
• Siemens Healthineers
• Sophysa
• Spiegelberg GmbH & Co.
   

Arachnoid Cysts Treatment Industry News:

• In February 2024, Royal Philips and magnetic resonance imaging (MRI) software solutions company Synthetic MR announced the launch of Smart Quant Neuro 3D– a major advance in objective decision support for diagnosis and therapy assessment of brain disorders like multiple sclerosis (MS), traumatic brain injury (TBI), and dementia. Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
   
• In April 2022, Imeka announced a collaboration with GE Healthcare to expand the capabilities of magnetic resonance imaging (MRI) and advance precision medicine for brain health. GE Healthcare integrated Imeka's non-invasive neuroimaging technology into the BrainWave advanced diffusion processing package to allow researchers and clinicians to analyze diffusion MRI signals in the brain in greater detail.
   

The arachnoid cysts treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Intracranial arachnoid cysts
• Spinal arachnoid cysts

Market, By Diagnosis

• CT scan
• MRI scan
• Prenatal ultrasound
• Other diagnosis

Market, By Treatment Type

• Endoscopic cysts fenestration
• Fenestration
• Permanent drainage system surgery

Market, By End-use

• Hospitals
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa